Navigation Links
Regado Biosciences, Inc. to Present at the Sofinnova Japan Biopharma Partnering Conference in Tokyo, Japan
Date:9/28/2011

nt (the Watson-Crick base pair complement of a fraction of the agent to be controlled), which can bind to the aptamer, removing it from its target and reversing its biologic effects.  Anivamersen is the complementary specific active control agent of pegnivacogin.  

More information can be found at www.regadobio.com

Contact:  Ellen McDonald, Chief Business Officer, Regado Biosciences, 1-908-580-2113, emcdonald@regadobio.com

Media Contact:
Tiberend Strategic Advisors, Inc.
1-212-827-0020
Andrew Mielach, amielach@tiberend.com
or
Madeleine Desmond, mdesmond@tiberend.com


'/>"/>
SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Regado Biosciences to Present at the Annual UBS Global Life Sciences Conference in New York City
2. Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
3. Regado Biosciences to Present at the Needham & Companys 10th Annual Healthcare Conference in New York City
4. Regado Biosciences, Inc. Announces Presentation of the Results of the RADAR Phase 2b Clinical Trial of Its Anticoagulant System REG1 at the i2 Summit During the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans
5. Regado Biosciences to Present at the 2011 RBC Capital Markets Healthcare Conference in New York City
6. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
7. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
8. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
9. Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania
10. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
11. Regado Biosciences to Present at the Stifel Nicolaus Healthcare Conference 2010 on September 16, 2010 in Boston, Massachusetts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 11, 2014  Major advances in radiation therapy ... being highlighted in a three-day Oncology Summit taking ... July, 2014.  Renowned national and international cancer experts from ... and exchange knowledge on modern technologies making treatment ... The Summit will address a ...
(Date:7/10/2014)... 11. Juli 2014  Dilon Technologies, ... die molekulare Bildgebung, einschließlich molekularer Bildgebung ... CE-Zulassung für sein Navigator ® -Gamma-Sondensystem ... das Produkt jetzt europaweit vertreiben. Dilon ... der europäischen Länder ausgedehnt und bereits ...
(Date:7/10/2014)...  The U.S. Department of Health and Human Services ... (UH) Case Medical Center Seidman Cancer Center totaling $4.7 ... improving care for patients with complex cancer. ... a unique model developed at UH to enhance care ... or demonstrated need for high health care utilization.  ...
Breaking Medicine Technology:Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4
... New to Antiretroviral Therapy Respond ... Similarly to Men and ... once-daily or twice-daily dosing of Abbott,s (NYSE:,ABT) protease inhibitor Kaletra(R) ... amount of HIV-1),and improving the immune system (increasing CD4 cells) ...
... a,biopharmaceutical company engaged in the discovery and development ... announced today,that Genentech, a collaborator, has moved a ... into a phase 1 clinical trial,that has begun ... and tolerability of both single and multiple doses ...
Cached Medicine Technology:Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 2Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 3Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 4Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 5Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 6Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 7Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 8Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial 2Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial 3
(Date:7/10/2014)... 11, 2014 Karen Middleton, Executive Director ... CEO of Planned Parenthood of the Rocky Mountains (PPRM), ... Udall and Representative Diana DeGette were in Washington, DC ... Lobby decision and keeping bosses out of women’s birth ... to the president today in Denver addressing issues related ...
(Date:7/10/2014)... The Capital Institute for Neurosciences at ... procedure in a clinical trial that delivers chemotherapy to ... , During the procedure, done at Capital Health Medical ... threaded a tiny catheter through the patient’s femoral artery ... and into the brain. Once the catheter reached the ...
(Date:7/10/2014)... 3 fatty acids had healthier joints than those fed ... acids, according to Duke Medicine researchers. , The findings, ... (10.1136/annrheumdis-2014-205601) on July 11, 2014, suggest that unhealthy ... to worsening osteoarthritis. , "Our results suggest that dietary ... in the link between obesity and osteoarthritis," said Farshid ...
(Date:7/10/2014)... More than 200 experts on aggression, who ... violence, will attend the 21st World Meeting of the ... at the Loews Atlanta Hotel, July 15-19. , ... meeting, which is held every other year on alternating ... leading scholars from more than 20 different countries, which ...
(Date:7/10/2014)... Canada (PRWEB) July 10, 2014 ... account for an increasing number of accidents in ... in Safety Reboot. The articles highlight safety issues ... estimated 317 million accidents occur on the job ... Three features continue to explore "preventable workplace accidents." ...
Breaking Medicine News(10 mins):Health News:Naral Pro-Choice Colorado & Planned Parenthood Of The Rocky Mountains Statement On Udall & Degette Staying In Dc To Introduce Legislation 2Health News:New Trial Delivers Chemotherapy to Brain Tumor Through Artery in Leg 2Health News:New Trial Delivers Chemotherapy to Brain Tumor Through Artery in Leg 3Health News:Omega 3 fatty acids lessen severity of osteoarthritis in mice 2Health News:Georgia State Hosts National Conference On Aggression 2Health News:Georgia State Hosts National Conference On Aggression 3Health News:Georgia State Hosts National Conference On Aggression 4Health News:Safety Reboot Magazine Focuses on: Why Extended Hours is Dangerous in the Workplace; Why Custodial Work Can be Dangerous; and Improving Safety for Roofers 2Health News:Safety Reboot Magazine Focuses on: Why Extended Hours is Dangerous in the Workplace; Why Custodial Work Can be Dangerous; and Improving Safety for Roofers 3
... the Black Death as the world's worst pandemic if the ... get life prolonging drugs. The illness has killed 25 million ... infected each day with HIV, which destroys the immune system. ... will die, pushing the death toll beyond the 40 million ...
... suffer from asphyxia, which can lead to brain injury, multiple ... cent of babies who suffer from a moderate lack of ... no effective treatments to reduce the risk of asphyxia at ... a baby's temperature may have beneficial effects. ,UK researchers ...
... in the alpha gene are the cause of premature menopause ... about 2% of the total population. ,The University of ... of a genetic test, which would allow women// with a ... at risk. They analysed DNA from women who had experienced ...
... undergoing coronary artery bypass surgery is rising, even though ... artery bypass surgery uses a blood vessel from another ... or clogged arteries in the heart. A buildup of ... known as atherosclerosis. ,In the new study, ...
... FDA issued a statement about the potential for depression and ... reports say that the 15-year-old pilot who crashed his plane ... investigators don't know whether or not the teen, Charles J. ... death. Blood tests should reveal if the drug was in ...
... from the Institute of Health Sciences in Oxford found that ... likely to have a stillbirth, or to develop pre-eclampsia.// Taking ... the researchers. ,The researchers reviewed more than 23 ... benefits of anti-platelet drugs, of which low-dose aspirin is the ...
Cached Medicine News:
... precise and accurate Measurements! ,Patients are impressed ... examination when they see the doctor is ... - after only 5 minutes of proper ... proficient in the operation of this instrument ...
Great for small incisions and excision needs...
Multi-sided, Sharp all around...
...
Medicine Products: